On January 19, the board of directors of Eddy Pharmaceutical (688488) held the twenty-first meeting of the first board of directors, deliberated and passed the "Proposal on the Appointment of Senior Vice Presidents of the Company", and agreed to appoint Zhang Jing and Hong Qi as senior vice presidents of the company, and Hong Qi also served as the chief technology officer of the company, and the term of office was from the date of deliberation and approval of the board of directors to the expiration of the term of the first board of directors.
Zhang Jing: female, Chinese nationality, no right of abode abroad, born in October 1967, graduated from Wuhan University of Science and Technology majoring in clinical medicine. Ms. Zhang Jing worked at AbbVie China from January 2007 to December 2021, where she served as Director of AbbVie China's Antiviral Business Unit and Director of Strategy and Innovation Business Unit, responsible for the listing and operation of AbbVie China's anti-AIDS product Klizzie in China, the construction of the full ecological chain of AbbVie China's core products and the expansion of its innovative business. Previously, Ms. Zhang served as the Regional Manager of Schering-Baoya, the Regional Manager of Abbott Pharmaceuticals East District 1, and the Government Affairs Manager.
Hong Qi: Male, British nationality, born in January 1963, graduated from the Department of Chemistry of Nanjing University, Doctor of Chemistry, Postdoctoral Fellow, University of Oxford, UK. Mr. Hong Qi has served as an Associate Research Fellow at the Institute of Cellular and Molecular Life Sciences at newcastle University School of Medicine, Oxford University, a Senior Research Fellow, a Senior Research Fellow, Research Director and Chief Scientist in the DDS (Discovery and Development Solutions) Division of Merck Uk. From April 2013 to January 2018, Mr. Hong Qi joined Simcere Pharmaceuticals and Baccarat Biologics as Executive Technical Director, responsible for the evaluation and quality analysis of biomacromolecules, and from February 2018 to December 2021, he served as a consultant for biomacromolecules analysis and quality research. Mr. Hong Qi has been engaged in the research and development of chemical and biological drugs for more than 20 years, published more than 50 SCI professional papers, led and participated in the research and development of nearly 30 biological macromolecular drugs, and won the third prize of the National Natural Science Award of the People's Republic of China and the second prize of the National Education Commission for Scientific and Technological Progress.
According to the company's third quarter report of 2021, the company's net profit attributable to shareholders of listed companies in the third quarter of 2021 was -6,220,358.11 yuan, which was from profit to loss over the same period of the previous year.
According to the data of the digging network, Aidi Pharmaceutical is a high-tech pharmaceutical enterprise focusing on the pharmaceutical field and integrating drug research and development, production and sales.
This article originated from the digging shell network
![#澳洲留学泰酷啦! Addi International won the No.1 official certification of the "TOPPerformance Award in Greater China" of the University of South Australia!! Not much else[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)